Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment – Renal and Urology News
|
Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment
Renal and Urology News The CheckMate-214 trial demonstrated that combined immunotherapy with the checkpoint inhibitors nivolumab and ipilimumab results in superior outcomes—including significantly better objective response rate (ORR), progression-free survival (PFS), and … |
Endpoints News |
Bidding war erupts over Dimension’s gene therapy pipeline as Ultragenyx counters Regenxbio deal
Endpoints News A bidding war has suddenly erupted over one of the most damaged biotechs in gene therapy R&D. Just weeks after Regenxbio lined up the acquisition of Dimension Therapeutics $DMTX for , $86 million in stock, Ultragenyx $RARE has come along with an … |
|
Brammer Bio Completes Expansion of Cell and Gene Therapy …
PR Newswire (press release) CAMBRIDGE, Mass., Sept. 18, 2017 /PRNewswire/ — Brammer Bio (“Brammer”), a cell and gene therapy contract development and manufacturing organization … |
|
Brammer Bio Completes Expansion of Cell and Gene Therapy Clinical Manufacturing Facilities in Florida
Markets Insider CAMBRIDGE, Mass., Sept. 18, 2017 /PRNewswire/ — Brammer Bio (“Brammer”), a cell and gene therapy contract development and manufacturing organization (CDMO), today announced completion of its clinical capacity expansion in Alachua, Florida. |
|
Cells Programmed Like Computers to Fight Disease
Newswise (press release) Cells can be programmed like a computer to fight cancer, influenza, and other serious conditions – thanks to a breakthrough in synthetic biology by the University of Warwick. Newswise — Led by Professor Alfonso Jaramilloin the School of Life Sciences … |
|
Cells Programmed Like Computers to Fight Disease
Newswise (press release) Cells can be programmed like a computer to fight cancer, influenza, and other serious conditions – thanks to a breakthrough in synthetic biology by the University of Warwick. Newswise — Led by Professor Alfonso Jaramilloin the School of Life Sciences … |
|
UK biotech round-up: Autolus joins CAR–T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit
pharmaphorum “BCMA CAR–T cell therapies have shown considerable promise in early clinical studies. A dual-targeted approach may minimise the risk for antigen negative escape and extend CAR-T treatment to patients with low density of BCMA antigen on the surface … Syncona’s Autolus begins three T-cell cancer trials | Digitallook.comDIGITALLOOK Arix Bioscience plc notes positive clinical study announcements from Autolus LimitedMarkets Insider Arix Bioscience Notes Autolus Ltd’s Updates On Clinical Progress …London South East (registration) (blog) Stock Market Wire all 4 news articles » |